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Abstract

Results

Allogenic red blood cell (RBC) transfusions are a common and routinely
performed medical procedure, yet they are not risk free. Many of the
risks could be eliminated with a single product: artificial blood
substitutes. Scientists have been attempting to create artificial blood
substitutes for several years. Many products have gone through rigorous
clinical trials but ultimately never made it to market despite showing
potential. Today, there are two main types of artificial blood products:
hemoglobin-based and perfluorochemical-based. A total of seven studies
were evaluated for this study. Based on the literature review, there is
hopeful evidence that an artificial blood product might be viable for
future use. Further research will be crucial to the future of artificial blood
products in the field of transfusion medicine.

Two of the seven studies suggested artificial blood products
were either just as effective or more effective when
compared to allogenic RBC transfusions in emergency
situations, such as hemorrhagic shock. On the other hand,
several studies showed statistically significant differences in
clinical chemistry and/or hematologic values for patients
infused with RBC substitutes when compared to those
transfused with allogenic RBCs.

Most of the studies suggested artificial blood products are an
acceptable replacement for allogenic RBC transfusions

Table 1: Summary of Results

Limitations included significant variability between studies. Examples of
said variability include:
• Clinical setting
• Infusion criteria
• Outcome measurements

Introduction
Risks of allogenic RBC transfusions include, but are not limited to:
• Infectious disease transmission
• Transfusion related acute lung injury (TRALI)
• ABO incompatibility
Artificial blood products could potentially eliminate the aforementioned
issues. Types of artificial blood products include:
• Hemoglobin-based products
• Perfluorochemical-based products
This study addresses the important clinical question: In patients who
require RBC transfusions (P), is there a viable artificial blood product (I)
that would reduce the need for allogenic RBC transfusions (O) when
compared to traditional allogenic RBC transfusions (C)?

Methods
Two separate literature searches were completed through PubMed and
Google Scholar- one in November 2018 and one in January 2019. In total,
seven articles were selected for this study. Articles were selected based
on relevance, study design, outcome measurements, and results. The
seven selected articles include five randomized controlled trials and two
applied research animal studies. The seven selected articles examine
three different artificial blood products- HBOC-201, Hemospan, and
perfluorocarbons.
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1Vital signs includes temperature, blood pressure, respiratory
rate, and pulse oximetry
2AST levels increased in patients who received HBOC-201
3Blood pressure increased in patients who received HBOC201
4Serum urea nitrogen levels increased in patients who
received HBOC-201
5Temperature increased 1 degree C over baseline in patients
who received PFCs, which peaked 8 hours post infusion
6Blood pressure was significantly higher in subjects who
received 500mL Hemospan
7AST, ALT, GGT, and bilirubin differed between study groups

The studies suggested several advantages of artificial blood products,
when compared to traditional RBC transfusions. Examples of said
advantages include:
• Fewer required transfusions
• Fewer hypotensive episodes

Further research is needed. Future studies of artificial blood products
could include:
• Larger sample size in a well defined clinical setting
• Specifically defined infusion criteria
• Consistent outcome measurements (CBC, CMP, vital signs, etc)

Conclusion
There are currently no artificial blood products approved for use in the
United States. However, several products have shown promising results
in clinical trials. As such, the lack of artificial blood products is not due to
a lack of efficacy of such products. Artificial blood products could reduce
the risk of ABO incompatibility, contraction of infectious diseases, and
shortages of blood supplies. Further research will be crucial to the future
of artificial blood products in the field of transfusion medicine.

